PEGylated Aβ fab

Details PEGylated Aβ fab PEGylated Aβ fab

2008-01-09

2011-11-29

Kemmerer, Elizabeth C (Department: 1649)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Binds antigen or epitope whose amino acid sequence is...

C424S133100, C424S178100, C530S387100, C530S387900, C530S391100, C530S866000

Reexamination Certificate

active

08066999

ABSTRACT:
A method to treat conditions associated with Aβ peptide activity both prophylactically and therapeutically is described. The method employs humanized antibody fragments that specifically bind human Aβ peptide between amino acid positions 13-28, wherein the antibody fragments are covalently attached to a polyethylene glycol (PEG) molecule.

REFERENCES:
patent: 5004697 (1991-04-01), Pardridge
patent: 5278049 (1994-01-01), Baker et al.
patent: 5593846 (1997-01-01), Schenk et al.
patent: 5688651 (1997-11-01), Solomon
patent: 5753624 (1998-05-01), McMichael et al.
patent: 5766846 (1998-06-01), Schlossmacher et al.
patent: 5837672 (1998-11-01), Schenk et al.
patent: 5851996 (1998-12-01), Kline
patent: 5935927 (1999-08-01), Vitek et al.
patent: 6114113 (2000-09-01), McLaughlin-Taylor et al.
patent: 6114133 (2000-09-01), Seubert et al.
patent: 6218506 (2001-04-01), Krafft et al.
patent: 6284221 (2001-09-01), Schenk et al.
patent: 6582945 (2003-06-01), Raso
patent: 7575747 (2009-08-01), Davies et al.
patent: 2002/0009445 (2002-01-01), Du et al.
patent: 2002/0058267 (2002-05-01), Ozenberger et al.
patent: 2002/0086847 (2002-07-01), Chain
patent: 2002/0102261 (2002-08-01), Raso
patent: 2002/0136718 (2002-09-01), Raso
patent: 2004/0043418 (2004-03-01), Holtzman et al.
patent: 2004/0121415 (2004-06-01), King et al.
patent: 2004/0192893 (2004-09-01), Stavrianopoulos et al.
patent: 2004/0241164 (2004-12-01), Bales et al.
patent: 2004/0248197 (2004-12-01), Holtzman et al.
patent: 2004/0265308 (2004-12-01), Schenk
patent: 2005/0019330 (2005-01-01), Schenk
patent: 2006/0257396 (2006-11-01), Jacobsen
patent: 2006/0286066 (2006-12-01), Basran
patent: 0613007 (1994-02-01), None
patent: 0557270 (1995-05-01), None
patent: 1 257 584 (2001-02-01), None
patent: WO 89/01343 (1989-02-01), None
patent: WO 96/18900 (1996-06-01), None
patent: WO 96/25435 (1996-08-01), None
patent: WO 98/33815 (1998-08-01), None
patent: WO 98/34643 (1998-08-01), None
patent: WO 98/44955 (1998-10-01), None
patent: WO 99/27944 (1999-06-01), None
patent: WO 99/06066 (1999-11-01), None
patent: WO 99/60024 (1999-11-01), None
patent: WO 00/72880 (2000-12-01), None
patent: WO 00/77178 (2000-12-01), None
patent: WO 99/72876 (2000-12-01), None
patent: WO 01/10900 (2001-02-01), None
patent: WO 01/18169 (2001-03-01), None
patent: WO 01/62801 (2001-08-01), None
patent: WO 02/021141 (2002-03-01), None
patent: WO 02/046237 (2002-06-01), None
patent: WO 02/060481 (2002-08-01), None
patent: WO 03/015617 (2003-02-01), None
patent: WO 03/015691 (2003-02-01), None
patent: WO 03/016466 (2003-02-01), None
patent: WO 03/016467 (2003-02-01), None
patent: WO 03/090772 (2003-11-01), None
patent: WO 2004/071408 (2004-08-01), None
Bacskai et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci. 2002; 22(18):7873-7878.
Choy EHS et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatol. 2002; 41(10):1133-1137.
Holm et al. Mol Immunol. 2007; 44(6):1075-1084.
Humphreys DP et al. Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering. Protein Eng Des Sel. 2007; 20(5):227-234.
Mitchell et al. Curr Drug Targets. 2007; 8(7):832-838.
Rudikoff et al. Proc Natl Acad Sci USA, 1982; 79(6):1979-1983.
Vickers JC. Drugs Aging. 2002; 19(7):487-494.
Haass, C., et al., “Amyloid beta-peptide is produced by cultured cells during normal metabolism,”Nature, 359:322-325 (1992).
Ghiso, J., et al., “Epitope map of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimers disease,” Biochem J, 282 (Pt 2):517-522 (1992).
Seubert, P., et al., “Isolation and quantification of soluble Alzheimer's β peptide from biological fluids,”Nature, 359:325-327 (1992).
Gaskin, F., et al., “Human antibodies reactive with beta-amyloid protein in Alzheimer's disease,”J Exp Med, 177(4): 1181-1186 (1993).
Flood, JF, et al., “An amyloid β-protein fragment, Aβ [12-28], equipotently impairs post-training memory processing when injected into different limbic system structures,”Brain Res, 663(2):271-276 (1994).
Koudinov, A., et al., “The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma,”Biochem&Biophysic Res Comm, 205:1164-1171 (1994).
Schwarzman, AL et al., “Transthyretin sequesters amyloid β protein and prevents amyloid formation,”Proc Nall Acad Sci, 91:8368-8372, (1994).
Tabaton, M., et al., “Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid,”Biochem and Biophysi Res Comm, 200(3)1598-1603 (1994).
Walker, LC et al., “Labeling of cerebral amyloid in vivo with a monoclonal antibody,”J Neuropathol Exp Neurol, 53(4):377-383 (1994).
Wisniewski, T., et al., “Alzheimer's disease and soluble A beta,”Neurobiol Aging, 15(2):143-52 Review (1994).
Demattos, R.B., et al., “Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease,” Science, 295, pp. 2264-2267 (2002).
Giulian, D., et al., “Specific domains of β-amyloid from Alzheimer plaque elicit neuron killing in human microglia,”J Neutosci, 16 (19):6021-6037 (1996).
Hanan, E., et al., “Inhibitory effect of monoclonal antibodies on Alzheimer's βamyloid peptide aggregation,”Int J Exp Clin Invest, 3:130-133 (1996).
Solomon, B., et al., “Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide,”Proc Natl Acad Sci USA, 93(1):452-5 (1996).
Teller, JK et al., “Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome,”Nature Medicine, 2(1)93-95 (1996).
Tjernberg, Lo el al., “Arrest of beta-amyloid fibril formation by a pentapeptide ligand,”J Biol Chem, 271(15):8545-8548 (1996).
Winter G., et al., “Humanized antibodies”Immunology Today, 14(6):243-246 (1996).
Solomon, B., et al., “Disaggregation of Alzheimer beta-amyloid by site-directed mAb,”Proc Nat Acad Sci USA, 94(8):4109-4112 (1997).
El-Agnaf, OM et al., “The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide,”Eur J Biochem, 256(3):560-569 (1998).
He X-Y et al., “Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin,”J Immunol, 160:1029-1035 (1998).
Lambert, MP et al., “Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins,”Proc Natl Acad Sci, 95:6448-6453 (1998).
Solomon, B., et al., The amino terminus of the β-amyloid peptide contains an essential epitode for maintaining its solubility,Progress in Alzheimer's and Parkinson's Diseases, 205-211 (1998).
Soto, C., et al., “1-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications of Alzheimer's therapy,”Nature Medicine, 4(7):822-826(1998).
Blass, JP, “Immunologic treatment of Alzheimer's disease,”NEJM, 341:1694-1695 (1999).
Kuo, YM et al., “High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease,”Biochem Biophys Res Commun, 257(3):787-791 (1999).
McLean, C., et al., “Soluble pool of AP amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease,”Amer Neurological Assoc, 46:860-866 (1999).
Schenk, D., et al., “Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse,”Nature, 400:173-177 (1999).
St. George-Hyslop, P., et

Affiliated with

Also associated with

Rating

PEGylated Aβ fab does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with PEGylated Aβ fab, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PEGylated Aβ fab will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4310591